DNA Modification Methylases
"DNA Modification Methylases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzymes that are part of the restriction-modification systems. They are responsible for producing a species-characteristic methylation pattern, on either adenine or cytosine residues, in a specific short base sequence in the host cell's own DNA. This methylated sequence will occur many times in the host-cell DNA and remain intact for the lifetime of the cell. Any DNA from another species which gains entry into a living cell and lacks the characteristic methylation pattern will be recognized by the restriction endonucleases of similar specificity and destroyed by cleavage. Most have been studied in bacterial systems, but a few have been found in eukaryotic organisms.
Descriptor ID |
D015254
|
MeSH Number(s) |
D08.811.150.240 D08.811.913.555.500.350
|
Concept/Terms |
DNA Modification Methylases- DNA Modification Methylases
- Methylases, DNA Modification
- Modification Methylases, DNA
- Modification Methylases
- Methylases, Modification
- DNA Modification Methyltransferases
- Methyltransferases, DNA Modification
- Modification Methyltransferases, DNA
|
Below are MeSH descriptors whose meaning is more general than "DNA Modification Methylases".
Below are MeSH descriptors whose meaning is more specific than "DNA Modification Methylases".
This graph shows the total number of publications written about "DNA Modification Methylases" by people in this website by year, and whether "DNA Modification Methylases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 1 | 1 |
2012 | 0 | 2 | 2 |
2018 | 0 | 1 | 1 |
2019 | 1 | 1 | 2 |
2020 | 1 | 2 | 3 |
2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "DNA Modification Methylases" by people in Profiles.
-
Pediatric Gliosarcoma With and Without Neurofibromatosis Type 1: A Whole-exome Comparison of 2 Patients. J Pediatr Hematol Oncol. 2021 11 01; 43(8):e1201-e1204.
-
Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma. JCO Precis Oncol. 2021; 5.
-
Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment. J Neurol Sci. 2020 Nov 15; 418:117102.
-
MGMT-inhibitor in combination with TGF-?RI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells. Clin Transl Oncol. 2021 Mar; 23(3):612-619.
-
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. J Clin Oncol. 2020 10 10; 38(29):3407-3417.
-
DNA repair and cancer in colon and rectum: Novel players in genetic susceptibility. Int J Cancer. 2020 01 15; 146(2):363-372.
-
Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region. Clin Neurol Neurosurg. 2019 07; 182:92-97.
-
Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol. 2018 08; 136(2):273-291.
-
Biomarkers classification and therapeutic decision-making for malignant gliomas. Curr Treat Options Oncol. 2012 Dec; 13(4):417-36.
-
Drug resistance in glioblastoma: a mini review. Neurochem Res. 2012 Jun; 37(6):1192-200.